To conclude, we find that PPM1A-AS can work as an oncogene and can regulate several pathways in T-ALL, and thus may be provided as a potential clinic target for T-ALL patients with multiple gene mutations. Here, PPM1A is linked to acute lymphoblastic leukemia.